Cargando…

Acquired hemophilia A: emerging treatment options

Acquired hemophilia A is a rare autoimmune disorder caused by an autoantibody (inhibitor) to factor VIII (FVIII) that interferes with its coagulant function and predisposes to severe, potentially life-threatening hemorrhage. Disease management focuses on controlling bleeding, primarily with the use...

Descripción completa

Detalles Bibliográficos
Autores principales: Janbain, Maissaa, Leissinger, Cindy A, Kruse-Jarres, Rebecca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431493/
https://www.ncbi.nlm.nih.gov/pubmed/26056504
http://dx.doi.org/10.2147/JBM.S77332
_version_ 1782371362770255872
author Janbain, Maissaa
Leissinger, Cindy A
Kruse-Jarres, Rebecca
author_facet Janbain, Maissaa
Leissinger, Cindy A
Kruse-Jarres, Rebecca
author_sort Janbain, Maissaa
collection PubMed
description Acquired hemophilia A is a rare autoimmune disorder caused by an autoantibody (inhibitor) to factor VIII (FVIII) that interferes with its coagulant function and predisposes to severe, potentially life-threatening hemorrhage. Disease management focuses on controlling bleeding, primarily with the use of bypassing therapy and recombinant porcine FVIII, and permanently eradicating the autoantibody using various immunosuppressants. Treatment challenges include delayed diagnosis, difficulty achieving hemostasis and durable remissions, and complications associated with the use of hemostatic and immunosuppressive therapy in a primarily older patient population.
format Online
Article
Text
id pubmed-4431493
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-44314932015-06-08 Acquired hemophilia A: emerging treatment options Janbain, Maissaa Leissinger, Cindy A Kruse-Jarres, Rebecca J Blood Med Review Acquired hemophilia A is a rare autoimmune disorder caused by an autoantibody (inhibitor) to factor VIII (FVIII) that interferes with its coagulant function and predisposes to severe, potentially life-threatening hemorrhage. Disease management focuses on controlling bleeding, primarily with the use of bypassing therapy and recombinant porcine FVIII, and permanently eradicating the autoantibody using various immunosuppressants. Treatment challenges include delayed diagnosis, difficulty achieving hemostasis and durable remissions, and complications associated with the use of hemostatic and immunosuppressive therapy in a primarily older patient population. Dove Medical Press 2015-05-08 /pmc/articles/PMC4431493/ /pubmed/26056504 http://dx.doi.org/10.2147/JBM.S77332 Text en © 2015 Janbain et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Janbain, Maissaa
Leissinger, Cindy A
Kruse-Jarres, Rebecca
Acquired hemophilia A: emerging treatment options
title Acquired hemophilia A: emerging treatment options
title_full Acquired hemophilia A: emerging treatment options
title_fullStr Acquired hemophilia A: emerging treatment options
title_full_unstemmed Acquired hemophilia A: emerging treatment options
title_short Acquired hemophilia A: emerging treatment options
title_sort acquired hemophilia a: emerging treatment options
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431493/
https://www.ncbi.nlm.nih.gov/pubmed/26056504
http://dx.doi.org/10.2147/JBM.S77332
work_keys_str_mv AT janbainmaissaa acquiredhemophiliaaemergingtreatmentoptions
AT leissingercindya acquiredhemophiliaaemergingtreatmentoptions
AT krusejarresrebecca acquiredhemophiliaaemergingtreatmentoptions